Home > Publications database > Long-term Outcome After Helical Tomotherapy Following Breast Conserving Surgery for Ductal Carcinoma In Situ. > print

001     291812
005     20251119115817.0
024 7 _ |a 10.1177/15330338241264847
|2 doi
024 7 _ |a pmid:39043035
|2 pmid
024 7 _ |a 1533-0346
|2 ISSN
024 7 _ |a 1533-0338
|2 ISSN
037 _ _ |a DKFZ-2024-01524
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hauswald, Henrik
|0 P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0
|b 0
|e First author
|u dkfz
245 _ _ |a Long-term Outcome After Helical Tomotherapy Following Breast Conserving Surgery for Ductal Carcinoma In Situ.
260 _ _ |a Thousand Oaks, CA
|c 2024
|b Sage Publishing
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721827867_25597
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E055#LA:E055#
520 _ _ |a Background: This retrospective study aimed to investigate the outcomes and adverse events (AEs) associated with adjuvant radiotherapy with helical tomotherapy (hT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS). Methods: Twenty-eight patients with DCIS underwent postoperative hT between 2011 and 2020. hT was chosen since it provided optimal target coverage and tolerable organ-at-risk doses to the lungs and heart when tangential 3-dimensional conformal radiotherapy (3D-CRT) was presumed to provide unfavorable dosimetry. The median total (single) dose was 50.4 Gy (1.8 Gy). The median time between BCS and the start of hT was 5 weeks (range, 4-38 weeks). Statistical analysis included local recurrence-free survival, overall survival (OS), and secondary cancer-free survival. AEs were classified according to the Common Toxicity Criteria for Adverse Events, version 5. Results: The patients' median age was 58 years. The median follow-up period was 61 months (range, 3-123 months). The 1-, 3-, and 5-year OS rates were 100% each. None of the patients developed secondary cancer, local recurrence, or invasive breast cancer during follow-up. The most common acute AEs were dermatitis (n = 27), fatigue (n = 4), hyperpigmentation (n = 3), and thrombocytopenia (n = 4). The late AE primarily included surgical scars (n = 7) and hyperpigmentation (n = 5). None of the patients experienced acute or late AEs > grade 3. The mean conformity and homogeneity indices were 0.9 (range, 0.86-0.96) and 0.056 (range, 0.05-0.06), respectively. Conclusion: hT after BCS for DCIS is a feasible and safe form of adjuvant radiotherapy for patients in whom 3D-CRT is contraindicated due to unfavorable dosimetry. During follow-up, there were no recurrences, invasive breast cancer diagnoses, or secondary cancers, while the adverse effects were mild.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a DCIS
|2 Other
650 _ 7 |a breast cancer
|2 Other
650 _ 7 |a ductal carcinoma in situ
|2 Other
650 _ 7 |a helical tomotherapy
|2 Other
650 _ 7 |a intensity-modulated radiotherapy
|2 Other
650 _ 7 |a radiotherapy
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Mastectomy, Segmental
|2 MeSH
650 _ 2 |a Breast Neoplasms: radiotherapy
|2 MeSH
650 _ 2 |a Breast Neoplasms: surgery
|2 MeSH
650 _ 2 |a Breast Neoplasms: pathology
|2 MeSH
650 _ 2 |a Breast Neoplasms: mortality
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Radiotherapy, Intensity-Modulated: methods
|2 MeSH
650 _ 2 |a Radiotherapy, Intensity-Modulated: adverse effects
|2 MeSH
650 _ 2 |a Carcinoma, Intraductal, Noninfiltrating: radiotherapy
|2 MeSH
650 _ 2 |a Carcinoma, Intraductal, Noninfiltrating: surgery
|2 MeSH
650 _ 2 |a Carcinoma, Intraductal, Noninfiltrating: pathology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Radiotherapy, Adjuvant: adverse effects
|2 MeSH
650 _ 2 |a Radiotherapy, Adjuvant: methods
|2 MeSH
650 _ 2 |a Neoplasm Recurrence, Local: radiotherapy
|2 MeSH
650 _ 2 |a Neoplasm Recurrence, Local: pathology
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Radiotherapy Dosage
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
650 _ 2 |a Combined Modality Therapy
|2 MeSH
700 1 _ |a Schempp, Michael
|b 1
700 1 _ |a Liebig, Pauline
|b 2
700 1 _ |a Hoefel, Sebastian
|b 3
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 4
|u dkfz
700 1 _ |a Huber, Peter E
|0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028
|b 5
|u dkfz
700 1 _ |a Zwicker, Felix
|0 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c
|b 6
|e Last author
|u dkfz
773 _ _ |a 10.1177/15330338241264847
|g Vol. 23, p. 15330338241264847
|0 PERI:(DE-600)2220436-2
|p 15330338241264847
|t Technology in cancer research & treatment
|v 23
|y 2024
|x 1533-0346
856 4 _ |y OpenAccess
|u https://inrepo02.dkfz.de/record/291812/files/hauswald-et-al-2024-long-term-outcome-after-helical-tomotherapy-following-breast-conserving-surgery-for-ductal.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://inrepo02.dkfz.de/record/291812/files/hauswald-et-al-2024-long-term-outcome-after-helical-tomotherapy-following-breast-conserving-surgery-for-ductal.pdf?subformat=pdfa
909 C O |o oai:inrepo02.dkfz.de:291812
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TECHNOL CANCER RES T : 2022
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-01-03T21:48:32Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-01-03T21:48:32Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-29
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Double anonymous peer review
|d 2023-01-03T21:48:32Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-29
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-08-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
920 2 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 0
920 1 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 0
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 1
920 0 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-He78)E055-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21